LumiraDx Ltd

LumiraDX Ltd. is a next-generation point of care diagnostics company, which engages in the provision of an innovative diagnostic platform that supports a menu of tests with lab-comparable performance at the point of care. The firm's diagnostic testing solutions are being deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. It also has a comprehensive portfolio of COVID-19 testing solutions from the lab to point of need. The company was founded by Ronald Zwanziger, David Scott, and Jerry McAleer in 2014 and is headquartered in London, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LumiraDX Ltd. is a point of care diagnostics company, which engages in the provision of a diagnostic platform that supports tests with lab-comparable performance at the point of care. The company was founded by Ronald Zwanziger, David Scott, and Jerry McAleer in 2014 and is headquartered in Waltham, MA.

LumiraDx (NASDAQ: LMDX ) stock is taking a beating on Monday as investors prepare for the point-of-care diagnostics company's shares to be suspended tomorrow. LumiraDx notes that shares of LMDX are going to be suspended from the Nasdaq Exchange at the start of business on Tuesday.

Why Is LumiraDx (LMDX) Stock Down 13% Today?

LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards.

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

Roche Holding AG

Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.

Roche to buy part of LumiraDx diagnostics platform for $295 million

LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche.

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

Better Choice Co

Tellurian

Penny stocks can offer traders massive profits through their sheer price volatility. With prices below $5 per share, these tiny companies allow you to snap up many shares.

Best Penny Stocks Today? 3 To Watch Under $4 Now

Ardelyx

Altamira Therapeutics Ltd

Heron Therapeutics

When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks.

Penny Stocks To Buy? 4 Under $5 To Watch Right Now

LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimum Bid Price Requirement. The Notice states that because the Company has not regained compliance with the Minimum Bid Price Requirement, its securities are now subject to delisting from The Nasdaq Global Market.

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

LumiraDx (NASDAQ: LMDX ) stock is falling on Tuesday as the point-of-care diagnostics company's shares retreat from a rally on Monday. Investors will note that LMDX stock underwent a 217% rally on Monday.

Why Is LumiraDx (LMDX) Stock Down 35% Today?

LumiraDx (NASDAQ: LMDX ) stock is taking off on Monday with a new partnership with AstraZeneca (NASDAQ: AZN ) behind its rally. This collaboration has LumiraDx working together with AstraZeneca and Everton in the Community to set up the first community-based heart and lung screening hub in England.

Why Is LumiraDx (LMDX) Stock Up 323% Today?

Evelo Biosciences Inc

Generation Bio

Spruce Biosciences

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)

LumiraDx Limited (LMDX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

LumiraDx Limited (LMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes LumiraDx Limited (LMDX) a New Buy Stock

LumiraDx Limited (NASDAQ:LMDX ) Q2 2023 Earnings Call Transcript August 24, 2023 8:30 AM ET Company Participants Melissa Garcia - Vice President Corporate Counsel Ron Zwanziger - Chairman & Chief Executive Officer Dorian LeBlanc - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Jeffrey Cohen - Ladenburg Thalmann Andrew Cooper - Raymond James Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the LumiraDx Second Quarter 2023 Earnings Conference Call.

LumiraDx Limited (LMDX) Q2 2023 Earnings Call Transcript

LumiraDx Limited (LMDX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.58 per share a year ago.

LumiraDx Limited (LMDX) Reports Q2 Loss, Misses Revenue Estimates

LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023.

LumiraDx Reports Second Quarter 2023 Results

LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24

Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany

LumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests

LumiraDx submits a traditional 510(k) Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform, including the LumiraDx Instrument, with the LumiraDx SARS-CoV-2 Antigen (Ag) Ultra test, and the LumiraDx SARS-CoV-2 Ag Quality Control Swab Kit. LumiraDx submits a traditional 510(k) Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform, including the LumiraDx Instrument, with the LumiraDx SARS-CoV-2 Antigen (Ag) Ultra test, and the LumiraDx SARS-CoV-2 Ag Quality Control Swab Kit.

LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test

LumiraDx (NASDAQ: LMDX ) stock is heading higher on Wednesday morning after the company received approval for its Covid and RSV tests. The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) gave its approval to the company's test through its Coronavirus Test Device Approvals (CTDA) process.

Why Is LumiraDx (LMDX) Stock Up 30% Today?

BigBear.ai Holdings

Red Cat Holdings

Terawulf

Penny stocks are shares of companies that trade for less than $5. That's the standard definition of the term, but most traders who're familiar with the idea generally focus on cheaper stocks.

Best Penny Stocks to Buy Under $5? 4 To Watch Now

LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) today announced that it has received validation for use by the MHRA under the CTDA process for the LumiraDx SARS-CoV-2 Ag Ultra and LumiraDx SARS-CoV2 Ag & RSV tests. This milestone supports the UK in preparing for the upcoming respiratory season with tests that allow for rapid detection of SARS-CoV-2 infection as well as helping to differentiate between SARS-CoV-2 and RSV when respiratory symptoms are present.

LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests

LumiraDx Limited (NASDAQ:LMDX ) Q1 2023 Earnings Conference Call May 16, 2023 8:30 AM ET Company Participants Melissa Garcia - Vice President Corporate Counsel Ron Zwanziger - Chairman & Chief Executive Officer Dorian LeBlanc - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Andrew Cooper - Raymond James Matt Sykes - Goldman Sachs Jeffrey Cohen - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the LumiraDx First Quarter 2023 Earnings Call.

LumiraDx Limited (LMDX) Q1 2023 Earnings Call Transcript

LumiraDx Limited (LMDX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago.

LumiraDx Limited (LMDX) Reports Q1 Loss, Tops Revenue Estimates

LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023.

LumiraDx Reports First Quarter 2023 Results

LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Tuesday, May 16t h, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.

News for LumiraDx Ltd Stock (LMDX)